• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎抗病毒作用的动力学特征

Dynamical characterization of antiviral effects in COVID-19.

作者信息

Abuin Pablo, Anderson Alejandro, Ferramosca Antonio, Hernandez-Vargas Esteban A, Gonzalez Alejandro H

机构信息

Institute of Technological Development for the Chemical Industry (INTEC), CONICET-UNL, Santa Fe, Argentina.

Department of Management, Information and Production Engineering, University of Bergamo, Via Marconi 5, 24044, Dalmine (BG), Italy.

出版信息

Annu Rev Control. 2021;52:587-601. doi: 10.1016/j.arcontrol.2021.05.001. Epub 2021 May 28.

DOI:10.1016/j.arcontrol.2021.05.001
PMID:34093069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8162791/
Abstract

Mathematical models describing SARS-CoV-2 dynamics and the corresponding immune responses in patients with COVID-19 can be critical to evaluate possible clinical outcomes of antiviral treatments. In this work, based on the concept of virus spreadability in the host, antiviral effectiveness thresholds are determined to establish whether or not a treatment will be able to clear the infection. In addition, the virus dynamic in the host - including the time-to-peak and the final monotonically decreasing behavior - is characterized as a function of the time to treatment initiation. Simulation results, based on nine patient data, show the potential clinical benefits of a treatment classification according to patient critical parameters. This study is aimed at paving the way for the different antivirals being developed to tackle SARS-CoV-2.

摘要

描述2019冠状病毒病(COVID-19)患者中严重急性呼吸综合征冠状病毒2(SARS-CoV-2)动态变化及相应免疫反应的数学模型,对于评估抗病毒治疗的可能临床结果至关重要。在这项工作中,基于病毒在宿主体内的传播能力概念,确定抗病毒有效性阈值,以确定一种治疗方法是否能够清除感染。此外,宿主内的病毒动态变化——包括达到峰值的时间和最终单调下降的行为——被表征为开始治疗时间的函数。基于9例患者数据的模拟结果显示了根据患者关键参数进行治疗分类的潜在临床益处。本研究旨在为正在研发的不同抗SARS-CoV-2病毒药物铺平道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/91719a7e8cf9/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/c9d6b671d124/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/46a128f98248/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/c66dfdd3ed9f/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/b8e52faa9c75/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/df244cd48eec/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/d9607d23d7a5/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/a92388b06807/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/63365360e905/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/bd87b0fa633f/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/5b15c16535fb/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/6ce6bb4bbed7/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/02864bc75cef/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/2e637fe31a0d/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/cd7f2ac3d80f/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/91719a7e8cf9/gr15_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/c9d6b671d124/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/46a128f98248/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/c66dfdd3ed9f/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/b8e52faa9c75/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/df244cd48eec/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/d9607d23d7a5/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/a92388b06807/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/63365360e905/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/bd87b0fa633f/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/5b15c16535fb/gr10_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/6ce6bb4bbed7/gr11_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/02864bc75cef/gr12_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/2e637fe31a0d/gr13_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/cd7f2ac3d80f/gr14_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d967/8162791/91719a7e8cf9/gr15_lrg.jpg

相似文献

1
Dynamical characterization of antiviral effects in COVID-19.新型冠状病毒肺炎抗病毒作用的动力学特征
Annu Rev Control. 2021;52:587-601. doi: 10.1016/j.arcontrol.2021.05.001. Epub 2021 May 28.
2
Characterization of SARS-CoV-2 dynamics in the host.新冠病毒在宿主体内的动态特征
Annu Rev Control. 2020;50:457-468. doi: 10.1016/j.arcontrol.2020.09.008. Epub 2020 Oct 6.
3
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
4
Impulsive Neural Control to Schedule Antivirals and Immunomodulators for COVID-19.用于安排新冠肺炎抗病毒药物和免疫调节剂的冲动神经控制
Proc IEEE Conf Decis Control. 2022 Dec;2022:5633-5638. doi: 10.1109/cdc51059.2022.9992454. Epub 2023 Jan 10.
5
Oral antiviral treatments for COVID-19: opportunities and challenges.COVID-19 的口服抗病毒治疗:机遇与挑战。
Pharmacol Rep. 2022 Dec;74(6):1255-1278. doi: 10.1007/s43440-022-00388-7. Epub 2022 Jul 25.
6
Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.基于结构的 SARS-CoV-2 鸟嘌呤-N7 甲基转移酶(nsp14)的虚拟筛选和分子动力学模拟,以鉴定针对 COVID-19 的抗病毒抑制剂。
J Biomol Struct Dyn. 2021 Aug;39(13):4582-4593. doi: 10.1080/07391102.2020.1778535. Epub 2020 Jun 22.
7
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.高危 COVID-19 患者的抗病毒和免疫调节干扰素-β:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Sep 3;22(1):584. doi: 10.1186/s13063-021-05367-6.
8
Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients.基于数据驱动的 SARS-CoV-2 感染多尺度数学建模揭示了 COVID-19 患者之间的异质性。
PLoS Comput Biol. 2021 Nov 24;17(11):e1009587. doi: 10.1371/journal.pcbi.1009587. eCollection 2021 Nov.
9
screening of plant-derived antivirals against main protease, 3CL and endoribonuclease, NSP15 proteins of SARS-CoV-2.筛选植物来源的抗病毒药物,针对 SARS-CoV-2 的主要蛋白酶、3CL 和内切核酸酶 NSP15 蛋白。
J Biomol Struct Dyn. 2022 Jan;40(1):86-100. doi: 10.1080/07391102.2020.1808077. Epub 2020 Sep 8.
10
[Umifenovir and coronavirus infections: a review of research results and clinical practice].[乌米芬诺尔与冠状病毒感染:研究结果与临床实践综述]
Ter Arkh. 2020 Dec 26;92(11):91-97. doi: 10.26442/00403660.2020.11.000713.

引用本文的文献

1
Multi-objective control to schedule therapies for acute viral infections.用于安排急性病毒感染治疗方案的多目标控制
J Math Biol. 2025 Feb 4;90(2):25. doi: 10.1007/s00285-025-02188-y.
2
A biomathematical model of SARS-CoV-2 in Syrian hamsters.叙利亚仓鼠中新冠病毒的生物数学模型。
Sci Rep. 2024 Dec 18;14(1):30541. doi: 10.1038/s41598-024-80498-9.
3
A theory for viral rebound after antiviral treatment: A study case for SARS-CoV-2.抗病毒治疗后病毒反弹的理论:以严重急性呼吸综合征冠状病毒2为例的研究

本文引用的文献

1
Cardiovascular implications of COVID-19 versus influenza infection: a review.COVID-19 与流感感染的心血管影响:综述。
BMC Med. 2020 Dec 18;18(1):403. doi: 10.1186/s12916-020-01816-2.
2
Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model.利用 COVID-19 特异性模型计算无症状感染者以估计群体免疫阈值。
PLoS One. 2020 Dec 16;15(12):e0242132. doi: 10.1371/journal.pone.0242132. eCollection 2020.
3
COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data.
Math Biosci. 2025 Jan;379:109339. doi: 10.1016/j.mbs.2024.109339. Epub 2024 Nov 20.
4
Response of vaccination on community transmission of COVID-19: a dynamical approach.疫苗接种对新冠病毒社区传播的影响:一种动态方法。
Eur Phys J Spec Top. 2022;231(18-20):3749-3765. doi: 10.1140/epjs/s11734-022-00652-0. Epub 2022 Aug 16.
5
Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.抗病毒疗法对严重急性呼吸综合征冠状病毒2高传播性变体的有效性:一项建模与模拟研究
Front Pharmacol. 2022 Feb 9;13:816429. doi: 10.3389/fphar.2022.816429. eCollection 2022.
6
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.瑞德西韦、洛匹那韦/利托那韦和法匹拉韦治疗新型冠状病毒肺炎的疗效:一项系统评价
Int J Gen Med. 2021 Nov 23;14:8557-8571. doi: 10.2147/IJGM.S332458. eCollection 2021.
COVID-19 病死率及其人口统计学和社会经济影响因素:基于国家级数据的全球空间回归分析。
BMJ Open. 2020 Nov 3;10(11):e043560. doi: 10.1136/bmjopen-2020-043560.
4
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.抗病毒治疗的效力和时机是决定 SARS-CoV-2 脱落持续时间和炎症反应强度的决定因素。
Sci Adv. 2020 Nov 20;6(47). doi: 10.1126/sciadv.abc7112. Print 2020 Nov.
5
Characterization of SARS-CoV-2 dynamics in the host.新冠病毒在宿主体内的动态特征
Annu Rev Control. 2020;50:457-468. doi: 10.1016/j.arcontrol.2020.09.008. Epub 2020 Oct 6.
6
In-host Mathematical Modelling of COVID-19 in Humans.新冠病毒在人体内的宿主数学建模
Annu Rev Control. 2020;50:448-456. doi: 10.1016/j.arcontrol.2020.09.006. Epub 2020 Sep 30.
7
Current trends and future prediction of novel coronavirus disease (COVID-19) epidemic in China: a dynamical modeling analysis.中国新型冠状病毒病(COVID-19)疫情的现状和未来预测:动力学建模分析。
Math Biosci Eng. 2020 Apr 8;17(4):3052-3061. doi: 10.3934/mbe.2020173.
8
Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.定量评估瑞德西韦在感染 SARS-CoV-2 的恒河猴中的作用。
Virology. 2020 Nov;550:61-69. doi: 10.1016/j.virol.2020.07.015. Epub 2020 Aug 23.
9
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.抗病毒药物治疗新型冠状病毒(COVID-19)的临床疗效:综述。
J Infect Public Health. 2020 Sep;13(9):1187-1195. doi: 10.1016/j.jiph.2020.07.013. Epub 2020 Aug 3.
10
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.